Another Potential Food Allergy Treatment is Snapped Up by Big Pharma
Eli Lilly's $2.875 billion Merida acquisition signals Big Pharma's growing interest in biotechs developing next-generation food allergy treatments.
Useful takeaways from this story.
Eli Lilly's $2.875 billion Merida acquisition signals Big Pharma's growing interest in biotechs developing next-generation food allergy treatments.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
Eli Lilly's $2.875 billion Merida acquisition signals Big Pharma's growing interest in biotechs developing next-generation food allergy treatments.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.